Stock Events

Crossject 

€4.72
8
+€0.04+0.96% Today

Statistics

Day High
4.75
Day Low
4.61
52W High
5
52W Low
3.2
Volume
87,031
Avg. Volume
40,604
Mkt Cap
132.26M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

21SepExpected
Q4 2019
Q2 2020
Q4 2020
Q2 2021
Q4 2021
Q2 2022
Q2 2023
-0.26
-0.17
-0.09
0
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALCJ.PA. It's not an investment recommendation.

About

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Show more...
CEO
Mr. Patrick Alexandre
Employees
90
Country
FR
ISIN
FR0011716265
WKN
000A1XEH4

Listings